InvestorsHub Logo
Followers 27
Posts 744
Boards Moderated 0
Alias Born 07/12/2012

Re: None

Tuesday, 05/21/2013 12:54:01 PM

Tuesday, May 21, 2013 12:54:01 PM

Post# of 346182
FDA probably saw some first-line data


(it being open-labeled) in addition to poring over the reconstituted second-line.

Why is that important? Well, it tells you that most likely the front line data are good. And if first-line comes in with excellent MOS, expect a MUCH harder pop than yesterday. A partner would be a given for Bavi second-line. Bang, another hard pop.

Poorly informed investors, shorts, and MM plays are common in all biotechs, especially PPHM. Look, most biotech stocks do decay in price. Shorting makes a lot of sense to hard-core traders. (Not my cup of tea, but some love it).

Most biotech stocks are under heavy gravitational pull. They go down a heck of lot more than they go up. That's where patience and science come in.

We can beat the shorts, the MMs, and the weak hands, by hanging tough and following the studies and inflection points carefully .

Frankly, I was personally shocked at Dew Diligence's poor attempt to pass off a simple Google search as "evidence" that there are "many" NSCLC drugs out there better than Bavi. Not one of his cited studies came anymore close to Bavi's MOS. More fundamentally, Bavi is NOT just a lung cancer drug. I mean, it's astounding how many people still think Bavi is JUST for NSCLC.

They never study the platform. Traders and dumb investors just follow the green shoots. Heck, we've all been there. And we also know that the fastest way to lose money in the market is to chase green shoots.

Patience pays BIG in the market, which is why most people lose money in the market.

All in my opinion, of course.

Best,

Joe





Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News